J&J dumps Aegis Group's Carat

Share this article:
Johnson & Johnson dumped Aegis Group's Carat as it began a root-and-branch review of its media planning and buying assignments, according to Advertising Age. Carat had handled media on a number of the Pfizer OTC brands being acquired by J&J. Those brands will be divided up among roster agencies that survive the review, Ad Age reported.

Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.